SIBP-01 + docetaxel + carboplatin

This is a combination regimen comprising **SIBP-01** (a trastuzumab biosimilar developed by Shanghai Institute of Biological Products), **docetaxel**, and **carboplatin**. SIBP-01 is a biosimilar to trastuzumab (Herceptin), a recombinant humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (**HER2**) on cancer cells. Docetaxel is a semi-synthetic taxane that promotes microtubule assembly and inhibits microtubule disassembly, leading to cell cycle arrest. Carboplatin is a platinum-based chemotherapy agent that causes cross-linking of DNA, leading to apoptosis. This combination is used for the treatment of **HER2-positive breast cancer**, specifically as neoadjuvant or adjuvant therapy for early or locally advanced disease. SIBP-01 acts primarily through blocking HER2-mediated proliferative signaling, inducing antibody-dependent cell-mediated cytotoxicity (ADCC), and inhibiting HER2 receptor cleavage; docetaxel interferes with microtubular dynamics; carboplatin induces DNA crosslinks[1][3][5][7].

Other names

trastuzumab biosimilar SIBP-01 + docetaxel + carboplatin